Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type
Status:
Recruiting
Trial end date:
2023-10-09
Target enrollment:
Participant gender:
Summary
The purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety
and efficacy of Sintilimab with P-GemOx (pegaspargase, gemcitabine and oxaliplatin) regimen
for newly diagnosed advanced extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)